HP-505

Last updated
HP-505
HP 505.svg
Identifiers
  • 3-phenyl-3H-spiro[isobenzofuran-1,4'-piperidine]
CAS Number
PubChem CID
ChemSpider
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C18H19NO
Molar mass 265.356 g·mol−1
3D model (JSmol)
  • C1(C2OC3(CCNCC3)C4=C2C=CC=C4)=CC=CC=C1
  • InChI=1S/C18H19NO/c1-2-6-14(7-3-1)17-15-8-4-5-9-16(15)18(20-17)10-12-19-13-11-18/h1-9,17,19H,10-13H2
  • Key:ZFJQWOMHWFYLPD-UHFFFAOYSA-N

HP-505 is a triple reuptake inhibitor that was investigated by Hoechst-Roussel Pharmaceuticals. [1] In mice, HP-505 was a potent inhibitor of tetrabenazine-induced ptosis which may indicate antidepressant activity. [2]

Contents

Pharmacology

HP-505 IC50 (μM) [1]
5-HT NE DA NE:5-HTDA:5-HT
0.19 ± 0.040.34 ± 0.10.66 ± 0.151.83.5

The inhibitory effect of HP-505 on serotonin reuptake is approximately 1.8 and 3.5 times stronger than on norepinephrine and dopamine, respectively. [1] Subsequent investigations have found that HP-505 acts on presynaptic dopamine transporters and is devoid of anticholinergic effects. [3]

Synthesis

The N-methylated analog is called HP-365 [59142-29-9].

An older synthesis is available, although more modern methods exist now: [4]

HP-365 patent: HP-365 synthesis.svg
HP-365 patent:

References

  1. 1 2 3 Meyerson LR, Ong HH, Martin LL, Ellis DB (June 1980). "Effect of antidepressant agents on beta-adrenergic receptor and neurotransmitter regulatory systems". Pharmacology, Biochemistry, and Behavior. 12 (6): 943–948. doi:10.1016/0091-3057(80)90457-8. PMID   6105676. S2CID   45400599.
  2. ↑ Klioze SS, Bauer VJ, Geyer HM (April 1977). "Synthesis of spiro[isobenzofuran-1(3H),4'-piperidines] as potential central nervous system agents. 2. Compounds containing a heteroatom attached to nitrogen". Journal of Medicinal Chemistry. 20 (4): 610–612. doi:10.1021/jm00214a039. PMID   850252.
  3. ↑ Puri SK, Mantione CR, Petko W, Ellis DB (1979). "Spiroisobenzofuran Piperidine Derivatives. Interaction with Pre- and Post-Synaptic Dopaminergic Sites". In Usdin E, Kopin IJ, Barchas J (eds.). Catecholamines: Basic and Clinical Frontiers. Pergamon. pp. 514–516. doi:10.1016/B978-1-4832-8363-0.50158-0. ISBN   978-1-4832-8363-0.
  4. ↑ Maier, C. A., Wünsch, B. (1 January 2002). "Novel Spiropiperidines as Highly Potent and Subtype Selective σ-Receptor Ligands. Part 1". Journal of Medicinal Chemistry. 45 (2): 438–448. doi:10.1021/jm010992z. ISSN   0022-2623. PMID   11784148.
  5. ↑ Victor J. Bauer & Raymond W. Kosley, Jr., U.S. patent 3,959,475 (1976 to CNA Holdings LLC).


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.